Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Amazon.com, Inc’s (AMZN) Earnings Miss Is Much Ado About Nothing

By Josh Enomoto, InvestorPlace Contributor

AMZN stock absorbed one of the worst blows of this year, but abandoning the ship that Amazon built would be a big mistake.

3 Ag Stocks That Will Surprise Investors in 2017

By Josh Enomoto, InvestorPlace Contributor

Ag stocks have been one of the worst-hit sectors in recent years, but signs of an industry-wide recovery have investors hungry for more.

3 Discount Airline Stocks That Are Hitting Strong Turbulence

By Josh Enomoto, InvestorPlace Contributor

Discount airline stocks face a host of challenges that will continue to pressure them even if they emerge from earnings season victorious.

3 Hotel Stocks That Could Be All Smoke and Mirrors

By Josh Enomoto, InvestorPlace Contributor

The huge equity splurge by China's HNA Group means nothing for hotel stocks like Marriott (MAR), Hyatt (H) and LaSalle (LHO).

3 Big Pharma Stocks That Are Looking a Little Pale

By Josh Enomoto, InvestorPlace Contributor

These Big Pharma stocks need to justify their big price tags after disappointing results: Bristol-Myers (BMY), Merck (MRK) and Eli Lilly (LLY).

Load More